BioInvent International AB is pocketing around SEK150 million (US$21.2 million) - before expenses - and making two prominent additions to its shareholders' register, via a directed offering of 5,434,800 shares.
No Abstract BioWorld International Correspondent Adocia SA raised €14 million (US$20.3 million) in a second funding round to continue development of its BioChaperone protein delivery technology, which is designed to prolong the localized activity of growth factors and other protein-based drugs at their sites of action. The company, based in Lyon, France, has filed investigational new drug applications on its first two development programs, and clinical trials are due to begin shortly.
F-star Biotechnologische Forschungs-und Entwicklungsges mbH added another €8 million (US$11.5 million) in a third closing of a Series A round that had previously yielded €9 million, spread across two tranches.
